Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 270 across all filing types
Latest filing 2025-11-25 Share Issue/Capital Cha…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release from BioVaxys Technology Corp. announcing the completion of a 'Debt Settlement Transaction' where the company issued common shares to settle outstanding indebtedness. This falls under the category of capital structure changes and financing activities. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most appropriate classification for announcements regarding new share issues and capital changes.
2025-11-25 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a private placement financing (LIFE Exemption). It details the number of units sold, the price, the use of proceeds, and mentions insider participation. This falls under the category of capital raising and financing activities.
2025-11-19 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a 'Debt Settlement Transaction' where the company is issuing common shares to creditors to settle outstanding debt. This falls under the category of capital structure changes and financing activities. It is not a report publication announcement, nor is it a share issue for public capital raising, but rather a specific debt-for-equity swap, which is best classified under Capital/Financing Update.
2025-11-14 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the conversion of outstanding unsecured convertible debentures into common shares, resulting in a share issuance and a change to the company’s capital structure. This fits squarely under “Share Issue/Capital Change” (Code: SHA), which covers announcements of new share issues or other capital changes. It is not reporting financial results, management changes, or regulatory filings that would fall under other categories.
2025-10-28 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the appointment of James Tartaglia to the Board of Directors and the resignation of an existing director. This clearly fits the category of Board/Management Information, which covers announcements of changes in the company’s board or senior management.
2025-10-08 English
Other material contracts (amended) - English.pdf
M&A Activity Classification · 1% confidence The document is a Third Amendment to an Asset Purchase Agreement between seller and purchaser, detailing specific contract changes (call option terms) for the ongoing asset purchase transaction. This is clearly related to an M&A transaction rather than a routine financial report, earnings release, or regulatory notice. Therefore it belongs in the M&A Activity category.
2025-09-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.